Pharmala Biotech Holdings Inc. (CSE:MDMA)
Canada · Delayed Price · Currency is CAD 0.2650
0.00 (0.00%)
Sep 18, 2026, 3:59 PM EST
Pharmala Biotech Holdings Cash Flow Statement
Financials in millions CAD. Fiscal year is September - August.
Millions CAD. Fiscal year is Sep - Aug.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Net Income | -1.61 | -2.18 | -0.82 | -0.78 | -0.99 | -3.76 |
Depreciation & Amortization | 0.01 | 0.05 | 0.01 | 0 | 0.01 | 0 |
Other Amortization | 0.11 | 0.06 | 0.06 | 0.05 | - | - |
Loss (Gain) on Equity Investments | - | 0.02 | - | - | - | - |
Stock-Based Compensation | 0.66 | 1.03 | 0.65 | 0.07 | 0.24 | 0.21 |
Provision & Write-off of Bad Debts | -0.2 | -0.19 | 0.02 | 0.02 | - | - |
Other Operating Activities | -0.01 | -0.02 | 0.16 | -0.07 | - | 3.13 |
Change in Accounts Receivable | -0.15 | 0.11 | -0.01 | -0.11 | -0.02 | - |
Change in Inventory | -0.22 | -0.02 | -0.23 | -0.01 | -0.12 | - |
Change in Accounts Payable | 0.3 | -0 | -0.03 | 0.21 | 0.23 | 0.21 |
Change in Unearned Revenue | - | - | - | - | 0.05 | - |
Change in Other Net Operating Assets | 0.13 | 0.08 | -0.12 | 0.28 | -0.03 | -0.04 |
Operating Cash Flow | -0.97 | -1.04 | -0.32 | -0.34 | -0.63 | -0.26 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Capital Expenditures | -0 | -0 | - | - | -0 | -0 |
Cash Acquisitions | - | - | - | - | - | 1.34 |
Sale (Purchase) of Intangibles | -0.06 | -0.03 | -0.23 | -0.51 | -0.99 | - |
Investment in Securities | 0.99 | -0.9 | - | - | - | - |
Other Investing Activities | - | - | - | - | - | -0.39 |
Investing Cash Flow | 0.93 | -0.94 | -0.23 | -0.51 | -0.99 | 0.94 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Issuance of Common Stock | 0.01 | 1.63 | 0.83 | 0.19 | - | 0.15 |
Other Financing Activities | - | -0.03 | -0.05 | - | - | 2.88 |
Financing Cash Flow | 0.01 | 1.6 | 0.77 | 0.19 | - | 3.03 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Net Cash Flow | -0.04 | -0.38 | 0.22 | -0.66 | -1.62 | 3.71 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Free Cash Flow | -0.97 | -1.05 | -0.32 | -0.34 | -0.63 | -0.26 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -76.63% | -172.85% | -31.04% | -63.84% | -804.87% | - |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.00 | -0.00 | -0.01 | -0.01 |
Levered Free Cash Flow | -0.4 | -0.17 | -0.08 | -0.48 | -1.18 | - |
Unlevered Free Cash Flow | -0.4 | -0.17 | -0.08 | -0.48 | -1.18 | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Change in Working Capital | 0.06 | 0.17 | -0.4 | 0.38 | 0.11 | 0.16 |